ZA201200716B - Modified factor ix polypeptides and uses thereof - Google Patents

Modified factor ix polypeptides and uses thereof

Info

Publication number
ZA201200716B
ZA201200716B ZA2012/00716A ZA201200716A ZA201200716B ZA 201200716 B ZA201200716 B ZA 201200716B ZA 2012/00716 A ZA2012/00716 A ZA 2012/00716A ZA 201200716 A ZA201200716 A ZA 201200716A ZA 201200716 B ZA201200716 B ZA 201200716B
Authority
ZA
South Africa
Prior art keywords
polypeptides
modified factor
factor
modified
Prior art date
Application number
ZA2012/00716A
Other languages
English (en)
Inventor
Alan Brooks
Chandra Patel
Xiaoqiao Jiang
Uwe Gritzan
Heiner Apeler
Jun Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201200716(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of ZA201200716B publication Critical patent/ZA201200716B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2012/00716A 2009-07-31 2012-01-30 Modified factor ix polypeptides and uses thereof ZA201200716B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
ZA201200716B true ZA201200716B (en) 2013-07-31

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/00716A ZA201200716B (en) 2009-07-31 2012-01-30 Modified factor ix polypeptides and uses thereof

Country Status (21)

Country Link
US (1) US20120164130A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2461821A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2013500726A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20120060209A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102573890A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2010278721A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012002072A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2769258A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2012000238A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20120052A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (3) CU20120018A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2012000030A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201290069A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP12011637A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT201200023A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2012DN00908A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2012001346A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20121643A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG178119A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011014890A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201200716B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655639T3 (es) 2006-12-15 2018-02-21 Baxalta GmbH Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
PT3581650T (pt) 2008-09-15 2023-03-08 Uniqure Biopharma B V Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
AU2010281453C1 (en) 2009-07-27 2019-08-15 Takeda Pharmaceutical Company Limited Blood coagulation protein conjugates
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG187171A1 (en) * 2010-07-30 2013-02-28 Baxter Int Nucleophilic catalysts for oxime linkage
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
PT2794665T (pt) * 2011-12-19 2018-01-24 Dilafor Ab Glicosaminoglicanos não anticoagulativos que compreendem unidade repetitiva de dissacáridos e sua utilização médica
WO2014081831A1 (en) * 2012-11-20 2014-05-30 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
CA2901928C (en) * 2013-03-13 2017-10-10 Eli Lilly And Company Modified canine leptin polypeptides
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
EP3490586B1 (en) * 2016-07-27 2025-03-26 The Children's Hospital of Philadelphia Compositions and methods for modulating factor ix function
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086091A2 (en) * 2001-04-25 2002-10-31 The Regents Of The University Of California Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector
NZ546733A (en) * 2003-12-03 2009-07-31 Novo Nordisk As Glycopegylated factor IX
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
WO2011014890A1 (en) 2011-02-03
GT201200023A (es) 2014-01-27
IN2012DN00908A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-04-03
SG178119A1 (en) 2012-03-29
CU20130058A7 (es) 2013-06-28
JP2013500726A (ja) 2013-01-10
BR112012002072A2 (pt) 2016-11-08
EA201290069A1 (ru) 2012-07-30
CR20120052A (es) 2012-06-04
ECSP12011637A (es) 2012-02-29
AU2010278721A1 (en) 2012-02-16
MX2012001346A (es) 2012-02-17
DOP2012000030A (es) 2012-02-29
CU20120018A7 (es) 2012-06-21
EP2461821A1 (en) 2012-06-13
PE20121643A1 (es) 2012-11-25
CN102573890A (zh) 2012-07-11
EP2461821A4 (en) 2013-07-03
CL2012000238A1 (es) 2012-10-05
US20120164130A1 (en) 2012-06-28
CA2769258A1 (en) 2011-02-03
CU20130057A7 (es) 2013-06-28
KR20120060209A (ko) 2012-06-11

Similar Documents

Publication Publication Date Title
ZA201200716B (en) Modified factor ix polypeptides and uses thereof
IL208718A0 (en) Modified factor ix polypeptides and uses thereof
ZA201303134B (en) Modified factor ix polypeptides and uses thereof
GB0916576D0 (en) Polypeptides and uses thereof
GB0916578D0 (en) Polypeptides and uses thereof
IL225740A0 (en) Adapted factor vii polypeptides and uses thereof
SI2483292T1 (sl) Variantni polipeptidi lovd in njihove uporabe
IL217551A0 (en) Bifunctional stapled polypeptides and uses thereof
IL201173A0 (en) Modified factor vii polypeptides and uses thereof
IL221278A0 (en) Chlorotoxin polypeptides and conjugates and uses thereof
SG10201913122WA (en) Modified relaxin polypeptides and their uses
IL207096A0 (en) Modified leptin polypeptides and their uses
PL2464656T3 (pl) Nowy peptyd i jego zastosowanie
EP2646059A4 (en) PROTEASE-DERIVABLE POLYPEPTIDES AND USES THEREOF
GB0905790D0 (en) Novel polypeptides and use thereof
ZA201007681B (en) Cd4-related polypeptides and methods of use
GB0909792D0 (en) Composition and uses thereof
GB0800698D0 (en) F2 polypeptides and usesthereof
GB0800701D0 (en) F10 Polypeptides and uses thereof
GB0800700D0 (en) F9 polypeptides and uses thereof
GB0800502D0 (en) Peptides and their uses
GB0816561D0 (en) Peptides and uses thereof
GB0910620D0 (en) Agents and uses thereof